Table 3.
Clinical activity score for the teprotumumab and placebo groups
| Study | Case | Baseline study eye |
Week 24 study eye |
Baseline fellow eye |
Week 24 fellow eye |
| A: Clinical activity score in patients who received teprotumumab | |||||
| 3 | 1 | 5 | 1 | 0 | 0 |
| 3 | 2 | 5 | 0 | 1 | 0 |
| 3 | 3 | 4 | 0 | 4 | 0 |
| 2 | 4 | 5 | 1 | 4 | 1 |
| 2 | 5 | 4 | 0 | 4 | 0 |
| 2 | 6 | 7 | 4 | 7 | 4 |
| 2 | 7 | 5 | 0 | 4 | 0 |
| 2 | 8 | 4 | 1 | 1 | 0 |
| 2 | 9 | 4 | 0 | 0 | 0 |
| 2 | 10 | 5 | 1 | 2 | 0 |
| Mean | 5 | 0.8 | 2.7 | 0.5 | |
| SD | 0.9 | 1.2 | 2.3 | 1.3 | |
| B: Clinical Activity Score in patients who received placebo | |||||
| Phase 3 | 1 | 7 | 3 | 7 | 3 |
| Phase 3 | 2 | 5 | 0 | 4 | 0 |
| Phase 3 | 3 | 5 | 2 | 5 | 2 |
| Phase 3 | 4 | 7 | 2 | 5 | 2 |
| Phase 3 | 5 | 5 | 5 | 4 | 4 |
| Phase 3 | 6 | 6 | 5 | 4 | 4 |
| Phase 2 | 7 | 5 | 1 | 5 | 1 |
| Phase 2 | 8 | 4 | 4 | 4 | 4 |
| Phase 2 | 9 | 4 | 5 | 3 | 0 |
| Phase 2 | 10 | 6 | 3 | 4 | 1 |
| Phase 2 | 11 | 6 | 5 | 6 | 5 |
| Phase 2 | 12 | 5 | 3 | 2 | 2 |
| Mean | 5.4 | 3.2 | 4.4 | 2.3 | |
| SD | 1 | 1.7 | 1.3 | 1.7 | |